Rare NRG1 Fusion Market Insights, Epidemiology, and Market Forecast

1. Rare NRG1 Fusion Market Insights, Epidemiology, and Market Forecast telegra.ph/Rare-NRG1-Fusion-Market-Insights-Epidemiology-and-Market-Forecast-04-12 consulting services April 12, 2021 Rare NRG1 fusion Market DelveInsight’s ‘Rare NRG1 Fusion Drugs Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Rare NRG1 Fusion, historical and forecasted epidemiology as well as the Rare NRG1 Fusion market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) Japan, and China. The Rare NRG1 Fusion market report provides current treatment practices, emerging drugs, Rare NRG1 Fusion market share of the individual therapies, current and forecasted Rare NRG1 Fusion market size from 2018 to 2030 segmented by eight major markets. The Report also covers the current Rare NRG1 Fusion treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. Rare NRG1 Fusion Market Companies- Overview NRG1 (Neuregulin 1) gene fusions are potentially actionable oncogenic drivers that are present in some solid tumors. NRG1 fusions result in ErbB-mediated pathway activation and present a rational therapeutic target. Oncogenic fusions of NRG1 may cause excess accumulation of the NRG1-fusion protein at the cell surface. This causes persistent activation of ErbB receptor tyrosine kinases that drive excess activity in the mTOR and MAPK pathways and promote tumorigenesis. The NRG1 gene encodes ligands for the ERBB2 (HER2)-ERBB3 heterodimeric receptor tyrosine kinase. Gene fusions of NRG1 1/2

2. such as CD74-NRG1 and SLC33A2-NRG1 have been found at low frequency in a wide range of carcinomas including lung, breast, colorectal, ovarian, and pancreatic cancers and with a wide range of fusion partners. CD74-NRG1 fusion gene has been identified in a portion of invasive mucinous adenocarcinomas (IMA) of the lung. However, the function of the CD74-NRG1 fusion gene in adenocarcinoma pathogenesis and the mechanisms by which it may impart protumorigenic characteristics to cancer stem cells (CSC) is still unclear. A range of NRG1 fusion partners beyond CD74 has been identified, and they also vary among cancer types. In NSCLC, other fusion partners include the SDC4, SLC3A2, and ATP1B1 genes. In other malignancies, the genes SETD4, TSHZ2, and ZMYM2 (ovarian cancer); ADAM9 and COX10-AS1 genes (breast cancer); and CDH1 and VTCN1 genes (pancreatic cancer) are among known fusion partners of NRG1. Rare NRG1 Fusion Diagnosis Fusions involving the neuregulin-1 gene (NRG1) were first identified by transcriptome sequencing of lung adenocarcinomas, which revealed fusion of CD74 to NRG1. NRG1- fusion proteins and genes in solid tumors are detected primarily using immunohistochemistry and fluorescence in situ hybridization (FISH) techniques, DNA next-generation sequencing (NGS), and targeted gene fusion panels on RNA. The gold standard for the detection of NRG1 gene fusions is RNA sequencing in comparison with DNA sequencing. Although fluorescence in situ hybridization (FISH) can be used as a pre- screening method for its detection, only genetic sequencing will allow the identification of the gene fusion. RNA-sequencing is associated with higher sensitivity for genetic rearrangements and can increase the detection of NRG1 gene fusions compared with DNA-based methods, which often do not cover the large introns in NRG1. Rare NRG1 Fusion Treatment Market NRG1 gene fusions result in the activation of ErbB2-/ErbB3-mediated signaling pathways and may function as oncogenic drivers. NRG1 fusions have emerged as a potential therapeutic target across multiple tumor types, including NSCLC. For NRG1 fusions, there are currently no approved targeted therapies. Standard therapy for advanced tumors harboring NRG1 fusions remains chemotherapy and/or immunotherapy or novel anti–PD-1 or anti–PD-L1 agents. The problem with utilizing these therapies is that response tends to be suboptimal for patients with NRG1 fusions. Several clinical reports have demonstrated that NRG1 fusions are a viable, actionable target in tumors, with responses seen on inhibition of ERBB family members. 2/2